Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors
- 3 December 1996
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 6 (23) , 2847-2852
- https://doi.org/10.1016/s0960-894x(96)00528-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- Results on New AIDS Drugs Bring Cautious OptimismScience, 1996
- Structure-based drug design of nonpeptidic P2 substituents for HIV-1 protease inhibitorsBioorganic & Medicinal Chemistry Letters, 1995
- Cyclic sulfone-3-carboxamides as novel P2-ligands for Ro 31-8959 based HIV-1 protease inhibitorsBioorganic & Medicinal Chemistry Letters, 1995
- Structure-Based Design of HIV-1 Protease Inhibitors: Replacement of Two Amides and a 10.pi.-Aromatic System by a Fused Bis-tetrahydrofuranJournal of Medicinal Chemistry, 1994
- The Development of Cyclic Sulfolanes as Novel and High-Affinity P2 Ligands for HIV-1 Protease InhibitorsJournal of Medicinal Chemistry, 1994
- Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligandsJournal of Medicinal Chemistry, 1993
- Cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitorsJournal of Medicinal Chemistry, 1993
- 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitorsJournal of Medicinal Chemistry, 1993
- 3'-Tetrahydrofuranylglycine as a novel, unnatural amino acid surrogate for asparagine in the design of inhibitors of the HIV proteaseJournal of the American Chemical Society, 1993